60,82 €
Deine Einschätzung
Edwards Lifesciences Corp. Aktie
Was spricht für und gegen Edwards Lifesciences Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von Edwards Lifesciences Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Edwards Lifesciences Corp. | 0,28 % | -1,79 % | -2,72 % | -10,90 % | -12,31 % | -40,26 % | 177,27 % |
Waters Corp. | 1,42 % | 0,84 % | -3,35 % | 15,46 % | -0,60 % | -11,18 % | 45,34 % |
QuidelOrtho Corp. | 1,45 % | 2,45 % | 6,09 % | -40,46 % | -38,37 % | -68,02 % | -28,31 % |
Illumina Inc. | 2,44 % | 4,11 % | -0,30 % | -11,48 % | -8,23 % | -69,06 % | -57,07 % |
Kommentare
News
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024.
Bernard Zovighian, chief executive officer
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient
Edwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024.
Highlights and Outlook
-
Q2 sales grew 7%; constant currency1 sales grew 8%
-
Q2 TAVR